Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

AMAG Pharmaceuticals

DB:AMU
Snowflake Description

Fair value with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AMU
DB
$210M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women’s health, anemia management, and cancer supportive care in the United States. The last earnings update was 31 days ago. More info.


Add to Portfolio Compare Print
  • AMAG Pharmaceuticals has significant price volatility in the past 3 months.
AMU Share Price and Events
7 Day Returns
2.1%
DB:AMU
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-52.4%
DB:AMU
-13.2%
DE Biotechs
-20.9%
DE Market
AMU Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
AMAG Pharmaceuticals (AMU) 2.1% -17.8% -51.2% -52.4% -73.9% -89.9%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • AMU underperformed the Biotechs industry which returned -13.2% over the past year.
  • AMU underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
AMU
Industry
5yr Volatility vs Market
Related Companies

AMU Value

 Is AMAG Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of AMAG Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for AMAG Pharmaceuticals.

DB:AMU Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.5%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:AMU
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 21%) (143.02%))
2.025
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
2
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (2 * 5.44%)
10.49%

Discounted Cash Flow Calculation for DB:AMU using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for AMAG Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:AMU DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.49%)
2020 -2.00 Analyst x1 -1.81
2021 -1.88 Analyst x3 -1.54
2022 25.80 Analyst x1 19.13
2023 25.60 Analyst x1 17.18
2024 66.90 Analyst x2 40.63
2025 98.95 Est @ 47.91% 54.39
2026 132.02 Est @ 33.42% 65.67
2027 162.75 Est @ 23.28% 73.27
2028 189.08 Est @ 16.18% 77.04
2029 210.27 Est @ 11.21% 77.54
Present value of next 10 years cash flows $421.00
DB:AMU DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $210.27 × (1 + -0.39%) ÷ (10.49% – -0.39%)
$1,925.10
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,925.10 ÷ (1 + 10.49%)10
$709.94
DB:AMU Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $421.00 + $709.94
$1,130.94
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,130.94 / 34.27
$33.01
DB:AMU Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:AMU represents 0.8899x of NasdaqGS:AMAG
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.8899x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 33.01 x 0.8899
€29.37
Value per share (EUR) From above. €29.37
Current discount Discount to share price of €5.46
= -1 x (€5.46 - €29.37) / €29.37
81.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price AMAG Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is €5.46 vs Future cash flow value of €29.37
Current Discount Checks
For AMAG Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • AMAG Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • AMAG Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for AMAG Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are AMAG Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:AMU PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-13.71
NasdaqGS:AMAG Share Price ** NasdaqGS (2020-04-03) in USD $6.14
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of AMAG Pharmaceuticals.

DB:AMU PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:AMAG Share Price ÷ EPS (both in USD)

= 6.14 ÷ -13.71

-0.45x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AMAG Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • AMAG Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does AMAG Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:AMU PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.45x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
92.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for AMAG Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on AMAG Pharmaceuticals's assets?
Raw Data
DB:AMU PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $8.42
NasdaqGS:AMAG Share Price * NasdaqGS (2020-04-03) in USD $6.14
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:AMU PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:AMAG Share Price ÷ Book Value per Share (both in USD)

= 6.14 ÷ 8.42

0.73x

* Primary Listing of AMAG Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AMAG Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess AMAG Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. AMAG Pharmaceuticals has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AMU Future Performance

 How is AMAG Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
92.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is AMAG Pharmaceuticals expected to grow at an attractive rate?
  • AMAG Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • AMAG Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • AMAG Pharmaceuticals's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:AMU Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:AMU Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 92.5%
DB:AMU Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts -8.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:AMU Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:AMU Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 219 118 17 5
2023-12-31 199 -1 1 6
2022-12-31 236 19 2 8
2021-12-31 249 13 -6 8
2020-12-31 258 4 -22 8
2020-04-06
DB:AMU Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 328 -126 -466
2019-09-30 326 -130 -287
2019-06-30 364 -61 -328
2019-03-31 432 -75 -233
2018-12-31 474 61 -169
2018-09-30 514 155 -148
2018-06-30 516 136 -239
2018-03-31 501 167 -227
2017-12-31 496 107 -205
2017-09-30 519 99 -216
2017-06-30 538 131 -45
2017-03-31 535 205 -31

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • AMAG Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • AMAG Pharmaceuticals's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:AMU Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from AMAG Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AMU Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 1.05 2.34 0.16 4.00
2023-12-31 0.65 1.07 0.25 4.00
2022-12-31 -0.21 0.93 -1.84 4.00
2021-12-31 -0.57 0.44 -1.48 4.00
2020-12-31 -1.22 -0.18 -3.43 4.00
2020-04-06
DB:AMU Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -13.71
2019-09-30 -8.40
2019-06-30 -9.56
2019-03-31 -6.77
2018-12-31 -4.92
2018-09-30 -4.29
2018-06-30 -6.89
2018-03-31 -6.52
2017-12-31 -5.88
2017-09-30 -6.22
2017-06-30 -1.29
2017-03-31 -0.90

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • AMAG Pharmaceuticals is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess AMAG Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
AMAG Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AMU Past Performance

  How has AMAG Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare AMAG Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • AMAG Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare AMAG Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare AMAG Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
AMAG Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from AMAG Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AMU Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 327.75 -466.46 286.87 23.20
2019-09-30 326.16 -287.28 284.21 21.87
2019-06-30 364.27 -328.33 290.93 16.95
2019-03-31 432.42 -233.32 279.30 18.46
2018-12-31 474.00 -169.34 277.42 16.95
2018-09-30 514.41 -147.86 270.17 15.06
2018-06-30 516.50 -238.89 259.61 9.71
2018-03-31 500.62 -227.33 251.06 18.83
2017-12-31 495.77 -205.15 225.84
2017-09-30 518.83 -216.45 223.60 18.75
2017-06-30 538.29 -44.54 215.23 17.42
2017-03-31 535.33 -30.88 213.65 16.06
2016-12-31 432.49 2.09 143.79 15.38
2016-09-30 489.24 15.28 217.72 24.39
2016-06-30 441.61 -21.51 207.46 14.12
2016-03-31 438.07 12.35 184.64 13.60
2015-12-31 418.28 32.78 156.04 13.98
2015-09-30 362.79 168.59 131.20 2.33
2015-06-30 292.14 190.63 102.61 11.12
2015-03-31 193.05 155.82 85.75 10.35
2014-12-31 124.38 135.82 72.94 10.89
2014-09-30 92.84 -10.85 62.09 9.41
2014-06-30 88.96 -12.45 60.57 9.58
2014-03-31 83.81 -12.81 58.29 9.77
2013-12-31 80.86 -9.60 54.99 11.57
2013-09-30 80.29 -9.63 52.80 11.93
2013-06-30 76.42 -13.46 51.81 12.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if AMAG Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if AMAG Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if AMAG Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess AMAG Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
AMAG Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AMU Health

 How is AMAG Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up AMAG Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • AMAG Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • AMAG Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of AMAG Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from AMAG Pharmaceuticals Company Filings, last reported 3 months ago.

DB:AMU Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 286.12 277.03 171.75
2019-09-30 480.63 273.12 191.54
2019-06-30 499.51 269.31 261.04
2019-03-31 614.72 265.58 266.51
2018-12-31 746.66 283.21 394.17
2018-09-30 762.25 279.38 427.53
2018-06-30 726.90 742.54 351.17
2018-03-31 740.00 738.56 370.56
2017-12-31 790.24 734.68 299.45
2017-09-30 800.31 755.42 394.10
2017-06-30 947.45 769.76 399.21
2017-03-31 924.09 985.35 558.40
2016-12-31 934.39 986.52 579.09
2016-09-30 937.95 987.81 614.07
2016-06-30 916.17 989.11 546.47
2016-03-31 922.97 990.48 480.21
2015-12-31 932.26 991.92 466.33
2015-09-30 919.96 1,005.16 442.87
2015-06-30 712.98 483.20 398.41
2015-03-31 671.18 489.24 361.14
2014-12-31 459.95 495.35 144.19
2014-09-30 196.98 165.78 386.24
2014-06-30 192.99 164.13 386.47
2014-03-31 191.10 162.56 385.47
2013-12-31 172.41 0.00 213.79
2013-09-30 174.25 0.00 213.54
2013-06-30 171.08 0.00 212.41
  • AMAG Pharmaceuticals's level of debt (96.8%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (107.1% vs 96.8% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • AMAG Pharmaceuticals has less than a year of cash runway based on current free cash flow.
  • Unable to confirm if AMAG Pharmaceuticals has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess AMAG Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. AMAG Pharmaceuticals has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AMU Dividends

 What is AMAG Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from AMAG Pharmaceuticals dividends.
If you bought €2,000 of AMAG Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate AMAG Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate AMAG Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:AMU Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:AMU Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as AMAG Pharmaceuticals has not reported any payouts.
  • Unable to verify if AMAG Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of AMAG Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as AMAG Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess AMAG Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can AMAG Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. AMAG Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AMU Management

 What is the CEO of AMAG Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bill Heiden
COMPENSATION $4,966,215
AGE 59
TENURE AS CEO 7.9 years
CEO Bio

Dr. William K. Heiden, also known as Bill, has been the Chief Executive Officer of AMAG Pharmaceuticals, Inc. since May 14, 2012 and serves as its President. Dr. Heiden serves as the Managing Director of Vitruvian Pharmaceuticals. Dr. Heiden served as the President of AMAG Pharmaceuticals, Inc. since May 14, 2012 until April 1, 2015. Dr. Heiden served as the Chief Executive Officer and President of GTC Biotherapeutics, Inc., since June 2010. He served as the President and Chief Executive Officer for Elixir Pharmaceuticals, Inc. from September 2004 to December 2008. Dr. Heiden joined Praecis Pharmaceuticals Inc. in May 9, 2002 and served as its President and Chief Operating Officer from May 9, 2002 to September 3, 2004. He joined Schering-Plough Corporation in 1987 and served as Vice President of Schering's Oncology/Biotech business unit. Mr. Heiden is an experienced pharmaceutical and biotechnology executive. From 1987 to 2002, he progressed through various positions of increasing responsibility at Schering-Plough Corporation (now Merck & Co.). He spent 15 years at Schering Plough where he held positions of increasing responsibility including Managing Director of a number of businesses in Europe and Canada, Vice President of Schering’s U.S. cardiovascular business unit. From April 1998 to July 1999, Dr. Heiden served as Vice President of marketing and sales at Key-Acute Coronary Syndromes, (now Millennium Pharmaceuticals, Inc.). He served as Schering's Director of Managed Health Care from 1996 to 1998, with responsibility for all Schering products within Managed Care for a twelve state region. From 1988 to 1996, he held a variety of management roles in Schering's International Division. He served as General Manager for Schering's business in the BeNeLux (Belgium, Netherlands and Luxembourg), Head of prescription product marketing at Schering Canada and General Manager for Schering Belgium. He served as the Chairman of the Board of rEVO Biologics since June 2010. He has been a Director of Atara Biotherapeutics, Inc. since November 23, 2015. He has been a Director of AMAG Pharmaceuticals, Inc since May 14, 2012. He served as a Director of rEVO Biologics since October 1, 2009. He served as Director of LFB S.A., and LFB Biotechnologies. He served as Director of Elixir Pharmaceuticals, Inc. since September 2004 and ConjuChem Biotechnologies, Inc., since January 2008. He is a member of the Duke University Healthcare Advisory Club. Dr. Heiden holds an B.A. in Business Administration from the University of Florida, his M.I.M. from the University of Louvain, Louvain, Belgium and an MBA from the Johnson School of Management, Cornell University. He holds BS from University of Florida. He holds MA and MS from University of Louvain.

CEO Compensation
  • Bill's compensation has increased whilst company is loss making.
  • Bill's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the AMAG Pharmaceuticals management team in years:

3.8
Average Tenure
47
Average Age
  • The tenure for the AMAG Pharmaceuticals management team is about average.
Management Team

Bill Heiden

TITLE
CEO, President & Director
COMPENSATION
$5M
AGE
59
TENURE
7.9 yrs

Ted Myles

TITLE
Executive VP
COMPENSATION
$2M
AGE
47
TENURE
4 yrs

Linda Lennox

TITLE
Vice President of Investor Relations & Corporate Communications

Joseph Vittiglio

TITLE
Executive VP of Legal Affairs & Quality
COMPENSATION
$1M
AGE
47
TENURE
4.7 yrs

Tracy Berns

TITLE
Chief Compliance Officer
TENURE
2.6 yrs

Amit Verma

TITLE
Vice President of Marketing
TENURE
6.8 yrs

Kelly Schick

TITLE
Senior VP & Chief Human Resources Officer

Tony Casciano

TITLE
Executive VP & Chief Commercial Officer
AGE
43
TENURE
3.6 yrs

Laura Williams

TITLE
Senior Vice President of Clinical Development
TENURE
2.6 yrs

Peter Bawin

TITLE
Senior VP & GM of Cord Blood Registry
TENURE
2.6 yrs
Board of Directors Tenure

Average tenure and age of the AMAG Pharmaceuticals board of directors in years:

6
Average Tenure
63
Average Age
  • The tenure for the AMAG Pharmaceuticals board of directors is about average.
Board of Directors

Gino Santini

TITLE
Independent Chairman
COMPENSATION
$283K
AGE
62
TENURE
6 yrs

Bill Heiden

TITLE
CEO, President & Director
COMPENSATION
$5M
AGE
59
TENURE
7.9 yrs

Davey Scoon

TITLE
Independent Director
COMPENSATION
$255K
AGE
72
TENURE
13.3 yrs

Jim Sulat

TITLE
Independent Director
COMPENSATION
$238K
AGE
69
TENURE
6 yrs

John Fallon

TITLE
Independent Director
COMPENSATION
$247K
AGE
71
TENURE
5.6 yrs

Rob Perez

TITLE
Independent Director
COMPENSATION
$230K
AGE
55
TENURE
11.3 yrs

Barbara Deptula

TITLE
Independent Director
COMPENSATION
$241K
AGE
64
TENURE
6.6 yrs

Kathrine O’Brien

TITLE
Independent Director
AGE
57
TENURE
1 yrs

Anne Phillips

TITLE
Independent Director
AGE
65
TENURE
1 yrs

David Johnson

TITLE
Independent Director
AGE
37
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Mar 20 Buy Armistice Capital LLC Company 16. Mar 20 16. Mar 20 24,000 €4.36 €104,736
27. Feb 20 Buy Armistice Capital LLC Company 25. Feb 20 25. Feb 20 36,000 €7.62 €274,326
28. Jan 20 Buy Armistice Capital LLC Company 24. Jan 20 27. Jan 20 90,000 €8.82 €785,119
13. Jan 20 Sell Armistice Capital LLC Company 09. Jan 20 09. Jan 20 -12,466 €11.20 €-139,628
13. Jan 20 Buy Armistice Capital LLC Company 09. Jan 20 10. Jan 20 30,466 €11.09 €326,758
04. Sep 19 Buy Kenneth Shea Individual 19. Aug 19 19. Aug 19 5,000 €10.28 €51,380
15. Aug 19 Buy Caligan Partners, LP Company 21. Jun 19 12. Aug 19 3,449,428 €10.09 €34,818,171
09. Aug 19 Buy Armistice Capital LLC Company 07. Aug 19 07. Aug 19 300,000 €6.62 €1,959,456
09. Aug 19 Buy Camber Capital Management LLC Company 07. Aug 19 09. Aug 19 385,000 €8.18 €2,701,060
27. Jun 19 Buy Armistice Capital LLC Company 25. Jun 19 27. Jun 19 498,016 €8.38 €3,885,089
29. May 19 Buy Julie Krop Individual 28. May 19 28. May 19 10,000 €8.87 €88,675
09. May 19 Buy William Heiden Individual 09. May 19 09. May 19 10,000 €9.53 €95,273
09. May 19 Buy Elizabeth Bolgiano Individual 09. May 19 09. May 19 5,000 €9.73 €48,660
X
Management checks
We assess AMAG Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. AMAG Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AMU News

Simply Wall St News

AMU Company Info

Description

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women’s health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company’s products candidates include Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women; AMAG-423, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent for the treatment of oral anticoagulants or low molecular weight heparin. It sells Feraheme to authorized wholesalers and specialty distributors. The company has a license agreement with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio LLC, Perosphere Pharmaceuticals Inc., Antares Pharma, Inc., and Abeona Therapeutics, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Details
Name: AMAG Pharmaceuticals, Inc.
AMU
Exchange: DB
Founded: 1981
$195,012,003
34,265,738
Website: http://www.amagpharma.com
Address: AMAG Pharmaceuticals, Inc.
1100 Winter Street,
Waltham,
Massachusetts, 02451,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS AMAG Common Stock Nasdaq Global Select US USD 11. Jun 1986
DB AMU Common Stock Deutsche Boerse AG DE EUR 11. Jun 1986
BRSE AMU Common Stock Berne Stock Exchange CH CHF 11. Jun 1986
Number of employees
Current staff
Staff numbers
440
AMAG Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 00:31
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/23
Last earnings filing: 2020/03/06
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.